Suchen
VolitionRX Ltd
VNRXZur Watchlist hinzufügen
1.400USD
+0.020+1.47%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
555.14KMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über VolitionRX Ltd Unternehmen
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
VolitionRX Ltd Informationen
BörsenkürzelVNRX
Name des UnternehmensVolitionRX Ltd
IPO-datumFeb 06, 2015
CEOButera (Salvatore Thomas)
Anzahl der mitarbeiter85
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 06
Addresse1489 West Warm Springs Road
StadtHENDERSON
BörseNASDAQ OMX – NASDAQ Basic Amex
LandUnited States of America
Postleitzahl89014
Telefon17024251561
Websitehttps://volition.com/
BörsenkürzelVNRX
IPO-datumFeb 06, 2015
CEOButera (Salvatore Thomas)
Führungskräfte von VolitionRX Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
170.16K
--
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.36K
--
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
20.68K
+8.40%
Mr. Nicholas Plummer
Mr. Nicholas Plummer
Group General Counsel
Group General Counsel
18.19K
-3.54%
Mr. Gael Forterre
Mr. Gael Forterre
Chief Commercial Officer
Chief Commercial Officer
16.56K
-2.28%
Mr. Rodney Gerard Rootsaert
Mr. Rodney Gerard Rootsaert
Corporate Secretary
Corporate Secretary
13.70K
-2.65%
Dr. Alan Colman, Ph.D.
Dr. Alan Colman, Ph.D.
Independent Director
Independent Director
12.24K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
170.16K
--
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.36K
--
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
20.68K
+8.40%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von VolitionRX Ltd?
Die fünf größten Anteilseigner von VolitionRX Ltd sind: Mr. Guy Archibald Innes
Wie viele Institutionen halten Anteile an VolitionRX Ltd (VNRX)?
Mit Stand vom 2026Q1 halten 66 Institutionen Anteile an VolitionRX Ltd, mit einem Gesamtmarktwert von etwa 1.13M, was 13.93% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -209799.00 gestiegen.